Description: Earli’s mission is to make cancer a benign experience,by catching and curing it early.
Liquid biopsies might indicate a tumor in a specific organ, but they cannot specify where in the organ the tumor it is. Early tumors are also often too small to image. Or the images show small lesions that could be either malignant or benign. For example, in lung cancer, 94% of lesions are benign, only 6% are malignant. Which 6% is often unclear. While patients are sent home to wait for repeat monitoring 6-12 months later, critical time may be lost to treat the cancer before it mutates further.
Earli is developing a radically new technique originally from Stanford University. Instead of searching for natural biomarkers that may, or often may not, exist, Earli biologically forces cancer cells to produce synthetic biomarkers that do not belong in the human body. That makes them directly localizable in a PET scan. The same technique may also apply to destroy the cancer, by forcing it to make itself vulnerable, or kill itself.
The new era of Synthetic Biopsy markers is here.
MBX Capital | Public Health Venture Capital
Make Early Cancer Detection Actionable, by Forcing the Cancer to Reveal Itself
Walker Comms - Communication for investors and founders
MBX Capital | Public Health Venture Capital